CJC-1295

What is CJC-1295?

CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH). It was engineered to increase growth hormone (GH) secretion while extending its half-life in the bloodstream through binding to albumin. This extended activity distinguishes it from natural GHRH and makes it a focus of research for longevity, fat loss, and performance optimization.

How Does CJC-1295 Work?

CJC-1295 stimulates the pituitary gland to release more growth hormone in pulses. Its design includes a drug affinity complex (DAC), which allows it to bind to albumin and extend activity for up to a week. This extended half-life means fewer injections compared to short-acting GHRH analogs. Increased GH levels lead to higher IGF-1 production, which supports growth, repair, and metabolism.

Chemical Properties

Potential Benefits of CJC-1295

• Growth Hormone Stimulation: Prolonged GH release through pituitary activation.
• Fat Loss Support: Enhanced lipolysis and metabolic regulation in research models.
• Recovery & Repair: Improved cellular repair, protein synthesis, and recovery after exertion.
• Anti-Aging Applications: Studied for its potential in preserving lean body mass and vitality with age.

Clinical Research & Findings

Research shows that CJC-1295 can sustain elevated growth hormone and IGF-1 levels for several days after a single injection. Animal and early human studies suggest potential benefits for fat reduction, improved sleep quality, enhanced recovery, and longevity-related pathways. Its ability to extend GH pulses without frequent dosing makes it a promising peptide in anti-aging and performance research.

Dosage & Research Protocols

• Research Dose: 1–2 mg subcutaneous injection
• Frequency: 2–3 times per week (with DAC form)
• Cycle Length: 8–12 weeks

CJC-1295 is often studied in combination with other peptides such as Ipamorelin to amplify GH release in synergistic research protocols.

FAQs

Is CJC-1295 legal in Canada?

Yes. CJC-1295 is legal for research use in Canada but not approved for human consumption.

How is CJC-1295 different from regular GHRH?

CJC-1295 is designed with a drug affinity complex (DAC) that extends its half-life, allowing fewer injections while sustaining GH release.

Can CJC-1295 be combined with other peptides?

Yes. It is often studied alongside Ipamorelin for synergistic effects on growth hormone secretion.

What form does CJC-1295 come in?

CJC-1295 is supplied in lyophilized powder form with ≥98% purity for laboratory research purposes.

Disclaimer

For laboratory use only. Not for human or veterinary use.

This peptide is intended strictly for research under controlled laboratory conditions. Buyers are responsible for ensuring legal and ethical compliance with institutional, local, and federal regulations.